KCNA3 and myeloid sarcoma: However, Kv1.3 colocalized with OPC marker NG2 in MS brain (Tegla et al., 2011), which suggests the beneficial effects of Kv1.3 blockade on MS may not be attributable solely to immune suppression; direct protection on OPCs may also contribute to the observed outcome.